Discount rates and drug value: A Q&A with Josh Cohen
All else being equal, people care more about outcomes that happen in the near future than about outcomes that happen later. The discount rate represents how much timing matters. We sit down with Josh Cohen, Deputy Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Research Professor of Medicine at Tufts University School of Medicine, to learn about how changes to the discount rate can alter how we value medicines.
Money talks: Your biotech compensation questions, answered
We wanted to expand RA Capital’s Gateway library of teaching modules to cover compensation-related topics, so we peppered experienced board member Steve Hoffman with questions about everything from managing stock option grants to tying bonuses to stretch goals. His answers did not disappoint.
Your New Year’s Resolution: Set useful corporate goals in 2024
It’s time to start thinking about New Year’s Resolutions. We asked ten experienced biotech board members what they consider useful, not useful, and downright irrelevant in terms of corporate goals. How do you know if goals are effective? And how important is it that they can actually be measured?
Everything you’ve always wanted to ask an Audit Committee member (but were too afraid to ask)
We asked three Gateway members who are or have been on Audit Committees – Kim Drapkin (CEO, Graphite Bio), Adam Mostafa (CFO, X4 Pharmaceuticals), and Sen Sundaram (CEO, Terns Pharmaceuticals) – to offer their best advice on Audit-related topics.
Toxic math: a British export that the US mustn’t import
It’s long been assumed that as long as NICE-like cost-effectiveness analyses stay on the other side of the ocean, our US biotech ecosystem will be fine. But in recent years, toxic math has begun to make its way to US soil. Peter Kolchinsky sat down with Jayson Dallas to get his take on NICE’s tactics, their increasingly global reach, and how biopharma can fight back.
COVID-19: When RA Capital’s “secret” maps go public
At RA Capital, we love our TechAtlas team and the super detailed Landscape Maps they create to help us understand what can otherwise be an overwhelming amount of information. These maps explain the comparative strengths and weaknesses of as many as hundreds of competitive and complementary technologies, drugs, devices, and diagnostics in various stages of development for a particular disease or condition. Think of them like medical treasure maps that lead to the most promising technologies and companies in any given disease area. You can probably understand why we can’t afford to do all that work and just publish the maps freely for the whole world to study.
Then COVID came along.
Movie night with RA Capital’s scientific cartographers
Members of TechAtlas work closely with the Investment Team and our portfolio companies to put data into context, identify breakthroughs, and develop conviction about how to solve particular problems given what we know of all the different technologies in development.